H

M

HEBBAR , Mohamed

Last name: HEBBAR

First name: Mohamed

January 1, 2019 (v1)

Journal article

Metadata-only

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

Bennouna, Jaafar Hiret, Sandrine Bertaut, Aurélie

Importance:Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer.Objective:To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab for patients with progression of metastatic colorectal cancer after bevacizumab plus...

Uploaded on: December 4, 2022
December 20, 2018 (v1)

Journal article

Metadata-only

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy, Thierry Hammel, Pascal Hebbar, Mohamed

BACKGROUND:Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with...

Uploaded on: December 4, 2022